UK biotech using a computational lab-in-the-loop platform to design therapeutic antibodies for undruggable targets.
| Date | Round | Amount |
|---|---|---|
| Mar 2026 | Series A UK biotech Antiverse raised a $9.3M Series A led by Soulmates Ventures to advance antibody discovery for undruggable disease targets. | $9.3M |
| Oct 2024 | Seed Cardiff techbio Antiverse raised a £3.5M seed led by i&i Biotech Fund and Kadmos Capital for its generative-AI antibody design platform. | $4.5M |
| Mar 2023 | Seed Antiverse raised GBP2.5M from InnoSpark, AngelHub, Kadmos Capital, Tomorrow Scale and existing investors including the Development Bank of Wales. | $2.8M |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.